Showing 1 - 20 results of 30,675 for search '(( a teer decrease ) OR ((( _ larger decrease ) OR ( _ ((small decrease) OR (a decrease)) ))))', query time: 0.51s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    Why does task performance decrease with burst length? by Swathi Anil (17382903)

    Published 2025
    “…See <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1013125#pcbi.1013125.s001" target="_blank">S1 Appendix</a>.…”
  6. 6
  7. 7
  8. 8

    The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

    Published 2025
    “…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. (D) As a result, the introduction of mutualistic interactions promotes a growth in complexity in communities where it was once established as low, while stopping the introduction of further mutualistic interactions causes a slight decrease in complexity. …”
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

    Published 2024
    “…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. …”
  14. 14
  15. 15
  16. 16

    DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx by Asmae El Maangar (19690522)

    Published 2025
    “…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …”
  17. 17

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  18. 18
  19. 19
  20. 20